Anne E Schuind (Anne Schuind)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 9

Top Topics

Immune Response

Hematopoietic Stem Cell

Top Venues

Human vaccines & immunotherapeutics

Influenza and other respiratory viruses

The Pediatric infectious disease journal

This page only lists publications with an associated author ORCID identifier.

Publications

Joon-Hyung Kim, Mamadou Drame, Thanyawee Puthanakit, Nan-Chang Chiu, Khuanchai Supparatpinyo, Li-Min Huang, Cheng-Hsun Chiu, Po-Yen Chen, Kao-Pin Hwang, Jasur Danier, Damien Friel, Bruno Salaun, Wayne Woo, David W Vaughn, Bruce L Innis, Anne E Schuind
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study. The Pediatric infectious disease journal 40 (9) (2022)
Alemnew F Dagnew, Peter Vink, Mamadou Drame, David O Willer, Bruno Salaun, Anne E Schuind
Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview. Human vaccines & immunotherapeutics (2021)
Edward A Stadtmauer, Keith M Sullivan, Mohamed El Idrissi, Bruno Salaun, Aránzazu Alonso Alonso, Charalambos Andreadis, Veli-Jukka Anttila, Adrian Jc Bloor, Raewyn Broady, Claudia Cellini, Antonio Cuneo, Alemnew F Dagnew, Emmanuel Di Paolo, HyeonSeok Eom, Ana Pilar González-Rodríguez, Andrew Grigg, Andreas Guenther, Thomas C Heineman, Isidro Jarque, Jae-Yong Kwak, Alessandro Lucchesi, Lidia Oostvogels, Marta Polo Zarzuela, Anne E Schuind, Thomas C Shea, Ulla Marjatta Sinisalo, Filiz Vural, Lucrecia Yáñez, Pierre Zachée, Adriana Bastidas
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Human vaccines & immunotherapeutics (2021)
Joon-Hyung Kim, John D Diaz-Decaro, Ning Jiang, Shinn-Jang Hwang, Eun Ju Choo, Maribel Co, Andrew Hastie, David Shu Cheong Hui, Junya Irimajiri, Jacob Lee, Edward Man-Fuk Leung, Haiwen Tang, Tomomi Tsuru, Philip Watson, Zhenhua Wu, Chong-Jen Yu, Yanfei Yuan, Toufik Zahaf, Anthony L Cunningham, Anne E Schuind
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. Human vaccines & immunotherapeutics 17 (7) (2021)
Amber Hsiao, Philip O Buck, Arnold Yee, John Hansen, Edwin M Lewis, Laurie L Aukes, Emad Yanni, Rafik Bekkat-Berkani, Anne E Schuind, Nicola P Klein
Retrospective study of the use of an influenza disease two-tiered classification system to characterize clinical severity in US children. Human vaccines & immunotherapeutics 16 (8) (2020)
Damien Friel, Mary Co, Thierry Ollinger, Bruno Salaun, Anne E Schuind, Ping Li, Karl Walravens, Francis A Ennis, David W Vaughn
Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system. Influenza and other respiratory viruses 15 (1) (2020)
Romulo Colindres, Valentine Wascotte, Alain Brecx, Christopher Clarke, Caroline Hervé, Joon-Hyung Kim, Myron J Levin, Lidia Oostvogels, Toufik Zahaf, Anne E Schuind, Anthony L Cunningham
Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Human vaccines & immunotherapeutics 16 (11) (2020)
Simon de Lusignan, Silvia Damaso, Filipa Matos Ferreira, Rachel Byford, Christopher McGee, Sameera Rankiri Pathirannehelage, Vishvesh Shende, Ivelina Yonova, Alexander C Schmidt, Anne E Schuind, Gaël Dos Santos
Brand-specific enhanced safety surveillance of GSK's Fluarix Tetra seasonal influenza vaccine in England: 2017/2018 season. Human vaccines & immunotherapeutics 16 (8) (2020)
Simon de Lusignan, Filipa Matos Ferreira, Silvia Damaso, Rachel Byford, Sameera Rankiri Pathirannehelage, Anne Yeakey, Ivelina Yonova, Anne E Schuind, Gaël Dos Santos
Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card. Human vaccines & immunotherapeutics 15 (5) (2019)